Log in to save to my catalogue

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support forma...

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support forma...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4930479

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

About this item

Full title

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

Publisher

Dordrecht: Springer Netherlands

Journal title

Angiogenesis (London), 2016-07, Vol.19 (3), p.389-406

Language

English

Formats

Publication information

Publisher

Dordrecht: Springer Netherlands

More information

Scope and Contents

Contents

Anti-vascular endothelial growth factor (VEGF) therapies have improved clinical outcomes for patients with cancers and retinal vascular diseases. Three anti-VEGF agents, pegaptanib, ranibizumab, and aflibercept, are approved for ophthalmic indications, while bevacizumab is approved to treat colorectal, lung, and renal cancers, but is also used off-...

Alternative Titles

Full title

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4930479

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4930479

Other Identifiers

ISSN

0969-6970

E-ISSN

1573-7209

DOI

10.1007/s10456-016-9515-8

How to access this item